title: [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer].
abstract: To investigate the efficacy and safety of bicalutamide (Casodex) with its clinically recommended dose, the randomized early phase II study was performed in 124 patients with prostatic cancer (stage C, D). The patients were given 50, 80 or 100 mg of bicalutamide orally once a day in fixed doses for 12 weeks; 122 patients were eligible for evaluation. The overall response rate was 50.0% (20/40), 61.0% (25/41) and 53.7% (22/41) in the 50 mg, 80 mg and 100 mg groups, respectively. The response rate in prostate lesion, bone and lymph node metastases was slightly higher in the 80 mg group than in the 50 mg and 100 mg groups. The proportion of patients showing a response with regard to serum PSA (CR and PR) was 84.2, 92.7 and 97.6% in the 50, 80 and 100 mg groups, respectively. The incidence of adverse reactions was 65.0, 61.0 and 61.0% in the 50, 80 and 100 mg groups, respectively, and there was no significant difference in overall safety rating in the three groups. Frequent adverse reactions were gynecomastia and breast pain. Only one patient in the 80 mg group was withdrawn due to shortness of breath. Serum concentrations of LH, testosterone and estradiol increased significantly after treatment. Bicalutamide was concluded to be effective and well tolerated in patients with prostatic cancer, and its recommended dose was 80 mg once daily.
authors.affiliation: Department of Urology, Center for Adult Diseases, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kotake
authors.forename: M
authors.initials: M
authors.lastname: Usami
authors.forename: S
authors.initials: S
authors.lastname: Isaka
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
authors.forename: E
authors.initials: E
authors.lastname: Nakano
authors.forename: A
authors.initials: A
authors.lastname: Okuyama
authors.forename: E
authors.initials: E
authors.lastname: Okajima
authors.forename: H
authors.initials: H
authors.lastname: Kanetake
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
authors.forename: Y
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: S
authors.initials: S
authors.lastname: Orikasa
authors.forename: Y
authors.initials: Y
authors.lastname: Sakata
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: K
authors.initials: K
authors.lastname: Koiso
authors.forename: Y
authors.initials: Y
authors.lastname: Honma
authors.forename: Y
authors.initials: Y
authors.lastname: Aso
authors.forename: K
authors.initials: K
authors.lastname: Oishi
authors.forename: O
authors.initials: O
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Naitoh
authors.forename: J
authors.initials: J
authors.lastname: Kumazawa
authors.forename: T
authors.initials: T
authors.lastname: Koyanagi
authors.forename: S
authors.initials: S
authors.lastname: Yachiku
authors.forename: Y
authors.initials: Y
authors.lastname: Shiraiwa
authors.forename: S
authors.initials: S
authors.lastname: Tsukagoshi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000813:Anilides / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014105:Tosyl Compounds
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide